Abstract

Background: ATP1A1 encodes an α1 isoform of Na+/K+-ATPase, which is expressed abundantly in kidneys and central nervous system. ATP1A1 variants may cause Na+/K+-ATPase loss of function and lead to a wide spectrum of phenotypes. This study aims to summarize the clinical and genetic features of ATP1A1 de novo mutation-related disorders and explore the potential correlations between phenotypes and genotypes.Methods: We analyzed two new cases harboring novel de novo ATP1A1 variants and reviewed all reported cases.Results: Both our probands had developmental delay, patient 1 accompanied with sleep disorders, irritability, and patient 2 with refractory seizures. They each had a novel de novo heterozygous missense variant, c.2797G>A[p.Asp933Asn] (NM_000701) and c.2590G>A[p.Gly864Arg] (NM_000701) respectively. Four patients with de novo ATP1A1 variants have been reported in two previous papers. Among them, three patients had refractory seizures and one patient had complex hereditary spastic paraplegia (HSP). Therefore, all six patients had developmental delay, and four of them had epilepsy. All variants located in the transmembrane regions M3, M4, M7, and M8 of ATP1A1 protein. Four patients with mutations in M3 and M7 had more severe phenotypes, including developmental delay and epileptic encephalopathy, three of them with hypomagnesemia, whereas two patients with mutations in M4 and M8 had milder phenotypes, only with mild developmental delay, without seizures or hypomagnesemia. Correcting hypomagnesemia had not controlled those seizures.Conclusions: Two novel de novo ATP1A1 variants identified in two patients here enriched the genotypic and phenotypic spectrum of ATP1A1 mutation-related disorder. Our findings suggest that hypomagnesemia in this disorder might relate to more severe phenotype and indicate more severe Na+/K+-ATPase dysfunction. Variations in M3 and M7 transmembrane regions were related to more severe phenotype than those in M4 and M8, which suggested that variations in M3 and M7 might cause more severe ATP1A1 functional defect.

Highlights

  • Na+/K+-ATPase is an integral membrane protein of a heterodimeric enzyme containing four isoforms of an α subunit (α1–α4) and three isoforms of a β subunit (β1–β3) [1]

  • It is suggested that ATP1A1 mutation-related disorders may have a wide spectrum of phenotypes, which may be related to the extensive expression and important functions of ATP1A1 in the nervous system [1, 4, 5]

  • EEG features of ATP1A1 mutation related epilepsy were not described in previous reports

Read more

Summary

Introduction

Na+/K+-ATPase is an integral membrane protein of a heterodimeric enzyme containing four isoforms of an α subunit (α1–α4) and three isoforms of a β subunit (β1–β3) [1] It can extrude three Na+ ions out of the cell and import two K+ ions into the cell using energy from the hydrolysis of one ATP in each pump cycle [2]. ATP1A1 encodes a transmembrane protein of 1,023 amino acids which is an α1 isoform of Na+/K+-ATPase. It locates in the human chromosome 1 region 1p2l→cen and practically ubiquitously expressed in body, especially in the kidneys and central nervous system (CNS) [1, 4]. This study aims to summarize the clinical and genetic features of ATP1A1 de novo mutation-related disorders and explore the potential correlations between phenotypes and genotypes

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call